Replies to post #33374 on Humanigen Inc (HGENQ)

[DonDonDonDon]

The NIH would not be violating their own protocol. "Unofficially" excluding patients would make the trial invalid.

If they are still treating patients with CRP>150mg/L or >85yo, it isn't a big deal. They represented about 25% of the LIVE-AIR trial. Still seems strange that they'd treat patients that aren't part of the primary endpoint. Maybe they had to keep the inclusion criteria the same in order to not start a new trial. This way they can look at the patients with CRP<150mg/L and <85yo from the whole ACTIV-5 as one patient population.